169 related articles for article (PubMed ID: 36715845)
1. HER2-positive invasive lobular carcinoma: a rare breast cancer which may not necessarily require anti-HER2 therapy. A population-based study.
Kada Mohammed S; Billa O; Ladoire S; Jankowski C; Desmoulins I; Poillot ML; Coutant C; Beltjens F; Dabakuyo S; Arnould L
Breast Cancer; 2023 May; 30(3):343-353. PubMed ID: 36715845
[TBL] [Abstract][Full Text] [Related]
2. Strong adverse effect of epidermal growth factor receptor 2 overexpression on prognosis of patients with invasive lobular breast cancer: a comparative study with invasive ductal breast cancer in Chinese population.
Wang T; Ma Y; Wang L; Liu H; Chen M; Niu R
Tumour Biol; 2015 Aug; 36(8):6113-24. PubMed ID: 25804795
[TBL] [Abstract][Full Text] [Related]
3. Specific sites of metastases in invasive lobular carcinoma: a retrospective cohort study of metastatic breast cancer.
Inoue M; Nakagomi H; Nakada H; Furuya K; Ikegame K; Watanabe H; Omata M; Oyama T
Breast Cancer; 2017 Sep; 24(5):667-672. PubMed ID: 28108967
[TBL] [Abstract][Full Text] [Related]
4. The prognosis of invasive ductal carcinoma, lobular carcinoma and mixed ductal and lobular carcinoma according to molecular subtypes of the breast.
Zhao H
Breast Cancer; 2021 Jan; 28(1):187-195. PubMed ID: 32812198
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the clinicopathological features of invasive ductal, invasive lobular, and mixed (invasive ductal + invasive lobular) carcinoma of the breast.
Zengel B; Yararbas U; Duran A; Uslu A; Elıyatkın N; Demırkıran MA; Cengiz F; Şimşek C; Postacı H; Vardar E; Durusoy R
Breast Cancer; 2015 Jul; 22(4):374-81. PubMed ID: 23925582
[TBL] [Abstract][Full Text] [Related]
6. Mixed Invasive Ductal and Lobular Carcinoma of the Breast: Prognosis and the Importance of Histologic Grade.
Metzger-Filho O; Ferreira AR; Jeselsohn R; Barry WT; Dillon DA; Brock JE; Vaz-Luis I; Hughes ME; Winer EP; Lin NU
Oncologist; 2019 Jul; 24(7):e441-e449. PubMed ID: 30518616
[TBL] [Abstract][Full Text] [Related]
7. Relative effectiveness of adjuvant chemotherapy for invasive lobular compared with invasive ductal carcinoma of the breast.
Marmor S; Hui JYC; Huang JL; Kizy S; Beckwith H; Blaes AH; Rueth NM; Tuttle TM
Cancer; 2017 Aug; 123(16):3015-3021. PubMed ID: 28382636
[TBL] [Abstract][Full Text] [Related]
8. Clinical characteristics and treatment outcomes of invasive ductal and lobular carcinoma: analyses of 54,832 taiwan cancer registry index cases.
Chen BF; Tsai YF; Lien PJ; Lin YS; Feng CJ; Chen YJ; Cheng HF; Tseng LM; Huang CC
Breast Cancer Res Treat; 2023 Oct; 201(3):547-560. PubMed ID: 37470893
[TBL] [Abstract][Full Text] [Related]
9. Comparison of clinical outcomes between luminal invasive ductal carcinoma and luminal invasive lobular carcinoma.
Adachi Y; Ishiguro J; Kotani H; Hisada T; Ichikawa M; Gondo N; Yoshimura A; Kondo N; Hattori M; Sawaki M; Fujita T; Kikumori T; Yatabe Y; Kodera Y; Iwata H
BMC Cancer; 2016 Mar; 16():248. PubMed ID: 27015895
[TBL] [Abstract][Full Text] [Related]
10. Comparative Long-term Study of a Large Series of Patients with Invasive Ductal Carcinoma and Invasive Lobular Carcinoma. Loco-Regional Recurrence, Metastasis, and Survival.
García-Fernández A; Lain JM; Chabrera C; García Font M; Fraile M; Barco I; Torras M; Reñe A; González S; González C; Piqueras M; Veloso E; Cirera L; Pessarrodona A; Giménez N
Breast J; 2015; 21(5):533-7. PubMed ID: 26190560
[TBL] [Abstract][Full Text] [Related]
11. Magnitude of trastuzumab benefit in patients with HER2-positive, invasive lobular breast carcinoma: results from the HERA trial.
Metzger-Filho O; Procter M; de Azambuja E; Leyland-Jones B; Gelber RD; Dowsett M; Loi S; Saini KS; Cameron D; Untch M; Smith I; Gianni L; Baselga J; Jackisch C; Bell R; Sotiriou C; Viale G; Piccart-Gebhart M
J Clin Oncol; 2013 Jun; 31(16):1954-60. PubMed ID: 23589556
[TBL] [Abstract][Full Text] [Related]
12. HER2-Positive Lobular Versus Ductal Carcinoma of the Breast: Pattern of First Recurrence and Molecular Insights.
Da Ros L; Moretti A; Querzoli P; Pedriali M; Lupini L; Bassi C; Carcoforo P; Negrini M; Frassoldati A
Clin Breast Cancer; 2018 Oct; 18(5):e1133-e1139. PubMed ID: 29759595
[TBL] [Abstract][Full Text] [Related]
13. Estrogen and progesterone receptor expression levels do not differ between lobular and ductal carcinoma in patients with hormone receptor-positive tumors.
Truin W; Roumen RMH; Siesling S; van de Vijver KK; Tjan-Heijnen VCG; Voogd AC
Breast Cancer Res Treat; 2017 Jul; 164(1):133-138. PubMed ID: 28365833
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of Single-Agent Chemotherapy for Patients with Advanced Invasive Lobular Carcinoma: A Pooled Analysis from Three Clinical Trials.
Pérez-Garcia J; Cortés J; Metzger Filho O
Oncologist; 2019 Aug; 24(8):1041-1047. PubMed ID: 30578311
[TBL] [Abstract][Full Text] [Related]
15. Clinical outcomes using accelerated partial breast irradiation in patients with invasive lobular carcinoma.
Shah C; Wilkinson JB; Shaitelman S; Grills I; Wallace M; Mitchell C; Vicini F
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e547-51. PubMed ID: 21640491
[TBL] [Abstract][Full Text] [Related]
16. Histologic tumor type as a determinant of survival in hormone receptor-positive, HER2-negative, pT1-3 invasive ductal and lobular breast cancer.
Göker M; Denys H; Hendrix A; De Wever O; Van de Vijver K; Braems G
Breast Cancer Res; 2023 Nov; 25(1):146. PubMed ID: 37993928
[TBL] [Abstract][Full Text] [Related]
17. Survival analysis in patients with invasive lobular cancer and invasive ductal cancer according to hormone receptor expression status in the Korean population.
Kwon D; Ko BK; Jung SP; Kim HK; Kim EK; Jung YS; Youn HJ; Lee SB
PLoS One; 2022; 17(1):e0262709. PubMed ID: 35051228
[TBL] [Abstract][Full Text] [Related]
18. The prognostic significance of metaplastic carcinoma of the breast (MCB)--a case controlled comparison study with infiltrating ductal carcinoma.
Lai HW; Tseng LM; Chang TW; Kuo YL; Hsieh CM; Chen ST; Kuo SJ; Su CC; Chen DR
Breast; 2013 Oct; 22(5):968-73. PubMed ID: 23787124
[TBL] [Abstract][Full Text] [Related]
19. Invasive lobular carcinoma of the breast: response to hormonal therapy and outcomes.
Rakha EA; El-Sayed ME; Powe DG; Green AR; Habashy H; Grainge MJ; Robertson JF; Blamey R; Gee J; Nicholson RI; Lee AH; Ellis IO
Eur J Cancer; 2008 Jan; 44(1):73-83. PubMed ID: 18035533
[TBL] [Abstract][Full Text] [Related]
20. Biomarker profile of invasive lobular carcinoma: pleomorphic versus classic subtypes, clinicopathological characteristics and prognosis analyses.
Zhang Y; Luo X; Chen M; Yang L; Lei T; Pu T; Wei B; Bu H; Zhang Z
Breast Cancer Res Treat; 2022 Jul; 194(2):279-295. PubMed ID: 35666367
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
